GLSI stock touches 52-week low at $10.52 amid market challenges

Published 25/03/2025, 16:48
GLSI stock touches 52-week low at $10.52 amid market challenges

Greenwich Lifesciences Inc (GLSI) stock has reached a 52-week low, trading at $10.52, as the biopharmaceutical company faces a challenging market environment. With a market capitalization of $141.7 million and a beta of 3.32, InvestingPro analysis indicates significantly higher volatility compared to the broader market. This price level represents a significant downturn for the company’s shares over the past year, with the stock experiencing a 1-year change of -46.46%. Despite the decline, GLSI maintains strong liquidity with a current ratio of 6.91, indicating robust short-term financial health. Investors are closely monitoring GLSI as it navigates through industry headwinds, with analysts setting a target price of $38, suggesting potential upside. InvestingPro subscribers can access 5 additional key insights and detailed financial metrics to make more informed investment decisions.

In other recent news, Greenwich LifeSciences has reported positive safety data from its Phase III clinical trial, FLAMINGO-01, for the immunotherapy treatment GLSI-100. The Data Safety Monitoring Board recommended the continuation of the trial without modifications, confirming no serious adverse events related to the drug. Preliminary safety data aligns with previous Phase IIb results, showing GLSI-100 is well-tolerated. Additionally, the company has started analyzing open label HLA data, revealing that about 46% of screened patients possess at least one HLA-A02 allele, supporting sample size estimates for the trial. The trial’s non-HLA-A02 arm has been expanded to 250 patients after recommendations from the steering committee and regulatory approval. Greenwich LifeSciences also announced the initiation of clinical sites in Germany, partnering with the German Breast Group to involve approximately 38 sites. The first patient in Germany has already been treated, marking a significant step in the trial’s expansion. The FLAMINGO-01 trial is led by Baylor College of Medicine and aims to evaluate the efficacy of GLSI-100 in preventing breast cancer recurrences globally.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.